Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Med Case Rep ; 18(1): 162, 2024 Mar 16.
Artigo em Inglês | MEDLINE | ID: mdl-38491548

RESUMO

BACKGROUND: Postoperative adjuvant systemic therapy with atezolizumab for lung cancer has been reported to be effective. Although myocarditis is a rare immune adverse event associated with atezolizumab, it can have a serious course and should be treated with caution. We herein report a case of fulminant myocarditis during adjuvant systemic therapy with atezolizumab. CASE PRESENTATION: The patient was a 49-year-old Asian woman. She was diagnosed with pT2aN1M0 stage IIB (Programmed Death Ligand 1(PD-L1), 50%) after surgery for right upper lobe lung adenocarcinoma. Atezolizumab was administered following platinum-based adjuvant chemotherapy. On day 14, the patient was hospitalized because of deterioration in her general condition caused by fever. On day 16, she developed dyspnea, which worsened, and on day 17, she experienced shock. Blood tests, echocardiography, and cardiac catheterization were performed, and the patient was diagnosed with cardiogenic shock due to myocarditis. Initial measures did not improve the patient's shock state. The patient was transferred to hospital for the use of an assistive circulatory system. Pulse steroid therapy was administered, and myocarditis showed a tendency toward improvement. A retrospective review of the patient's history revealed a decreased lymphocyte count and an increase in the neutrophil/lymphocyte ratio, which may be useful for detecting severe immune-related adverse events. The troponin levels were elevated, but creatine phosphokinase level remained within the normal range. CONCLUSION: Myocarditis can be fatal due to the rapid progression of symptoms. Close follow-up, a prompt diagnosis, and therapeutic intervention are important. Decreased lymphocyte counts, increased neutrophil/lymphocyte ratios, and the measurement of multiple myocardial biomarkers are considered useful for the early diagnosis of myocarditis.


Assuntos
Neoplasias Pulmonares , Miocardite , Feminino , Humanos , Pessoa de Meia-Idade , Adjuvantes Imunológicos/efeitos adversos , Anticorpos Monoclonais Humanizados/efeitos adversos , Quimioterapia Adjuvante/efeitos adversos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/complicações , Miocardite/induzido quimicamente
2.
Medicine (Baltimore) ; 100(32): e26907, 2021 Aug 13.
Artigo em Inglês | MEDLINE | ID: mdl-34397924

RESUMO

RATIONALE: Respiratory muscle paralysis due to low cervical spinal cord injury (CSCI) can lead to dysphagia. Noninvasive positive airway pressure (PAP) therapy can effectively treat this type of dysphagia. High-flow nasal cannula (HFNC) oxygen therapy can generate a low level of positive airway pressure resembling PAP therapy, it may improve the dysphagia. PATIENT CONCERNS: The patient was an 87-year-old man without preexisting dysphagia. He suffered a CSCI due to a dislocated C5/6 fracture, without brain injury, and underwent emergency surgery. Postoperatively (day 2), he complained of dysphagia, and the intervention was initiated. DIAGNOSIS: Based on clinical findings, dysphagia in this case, may have arisen due to impaired coordination between breathing and swallowing, which typically occurs in patients with CSCI who have reduced forced vital capacity. INTERVENTIONS: HFNC oxygen therapy was started immediately after the surgery, and swallowing rehabilitation was started on Day 2. Indirect therapy (without food) and direct therapy (with food) were applied in stages. HFNC oxygen therapy appeared to be effective because swallowing function temporarily decreased when the HFNC oxygen therapy was changed to nasal canula oxygen therapy. OUTCOMES: Swallowing function of the patient improved and he did not develop aspiration pneumonia. LESSONS: HFNC oxygen therapy improved swallowing function in a patient with dysphagia associated with respiratory-muscle paralysis following a CSCI. It may have prolonged the apnea tolerance time during swallowing and may have improved the timing of swallowing. HFNC oxygen therapy can facilitate both indirect and direct early swallowing therapy to restore both swallowing and respiratory function.


Assuntos
Medula Cervical/lesões , Transtornos de Deglutição/terapia , Oxigenoterapia/instrumentação , Insuficiência Respiratória/complicações , Paralisia Respiratória/complicações , Traumatismos da Medula Espinal/complicações , Idoso de 80 Anos ou mais , Cânula , Medula Cervical/diagnóstico por imagem , Transtornos de Deglutição/diagnóstico , Transtornos de Deglutição/etiologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Insuficiência Respiratória/diagnóstico , Insuficiência Respiratória/terapia , Paralisia Respiratória/diagnóstico , Paralisia Respiratória/terapia , Traumatismos da Medula Espinal/diagnóstico , Vértebras Torácicas
3.
Artigo em Inglês | MEDLINE | ID: mdl-22850727

RESUMO

The concept of "stabilization" of atmospheric CO(2) concentration is re-examined in connection with climate-change mitigation strategies. A new "zero-emissions stabilization (Z-stabilization)" is proposed, where CO(2) emissions are reduced to zero at some time and thereafter the concentration is decreased by natural removal processes, eventually reaching an equilibrated stable state. Simplified climate experiments show that, under Z-stabilization, considerably larger emissions are permissible in the near future compared with traditional stabilization, with the same constraint on temperature rise. Over longer time scales, the concentration and temperature decrease close to their equilibrium values, much lower than those under traditional stabilization. The smaller temperature rise at final state is essential to avoid longer-term risk of sea level rise, a significant concern under traditional stabilization. Because of these advantages a Z-stabilization pathway can be a candidate of practical mitigation strategies as treated in Part 2.


Assuntos
Poluição do Ar/prevenção & controle , Atmosfera/química , Dióxido de Carbono/análise , Internacionalidade , Mudança Climática , Previsões , Temperatura , Fatores de Tempo
4.
Artigo em Inglês | MEDLINE | ID: mdl-22850728

RESUMO

Following Part 1, a comparison of CO(2)-emissions pathways between "zero-emissions stabilization (Z-stabilization)" and traditional stabilization is made under more realistic conditions that take into account the radiative forcings of other greenhouse gases and aerosols with the constraint that the temperature rise must not exceed 2 °C above the preindustrial level. It is shown that the findings in Part 1 on the merits of Z-stabilization hold under the more realistic conditions. The results clarify the scientific basis of the policy claim of 50% reduction of the world CO(2) emissions by 2050. Since the highest greenhouse gas (GHG) concentration and temperature occur only temporarily in Z-stabilization pathways, we may slightly relax the upper limit of the temperature rise. We can then search for a scenario with larger emissions in the 21st century; such a scenario may have potential for practical application. It is suggested that in this Z-stabilization pathway, larger emissions in the near future may be important from a socioeconomic viewpoint.


Assuntos
Poluição do Ar/prevenção & controle , Atmosfera/química , Dióxido de Carbono/análise , Internacionalidade , Aerossóis/análise , Efeito Estufa
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...